20 listed sites across Australia (5); New Zealand (3); United States (12) - 30 Oct `24DR-01 antibody treatment for nonsegmental vitiligo

DR-01 antibody treatment for nonsegmental vitiligo

Official title: A Pilot, Safety and Clinical Activity, Phase 1b Study of DR-01 in Adults With Alopecia Areata or Vitiligo

Description:

DR-01 is an experimental intravenous antibody intended to reduce disease-driving immune cells. Researchers from Dren Bio hope it will lessen the attack on melanocytes and allow repigmentation. Possible risks include infusion reactions, headache, changes in blood counts, and infections; its full safety profile is not yet known.

People age 18 and older may qualify. The study is underway but is no longer accepting new participants. Dren Bio enrolled about 81 participants.

Start date: October 30, 2024

Completion date: May 01, 2027

Contact: Michael Rothenberg, MD, PhD

Tel.: Not reported

Email: Not reported

Link: Not reported

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference DR-01 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Safety of clinical trials. Can my child leave it for any reason?

    Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...

  • How can I cure vitiligo?

    Right now, there is no universal "cure," but we have entered a new era of treatment. Today, managing vitiligo isn’t just about "hiding" it; it’s about sophisticated science that...

  • Which therapy has minimal side-effects?

    Dead Sea climatotherapy is a unique and highly effective treatment option for vitiligo, offering a top-tier safety profile and natural therapeutic benefits. Its combination of p...